Pharma
-
AI's impact in drug discovery is coming fast, predicts GSK's Hal Barron
The R&D chief believes researchers will discover a new drug target using machine learning within the next two or three years.
By Ned Pagliarulo • Nov. 21, 2019 -
Takeda sees cell, gene therapy in its future. Is it too late?
Nearly a year on from completing its $62 billion Shire deal, Takeda is pitching investors on its plans to stay one of the industry's leading rare disease drug developers.
By Ned Pagliarulo • Nov. 20, 2019 -
Deep DiveBankrupt biopharmas are rare. 2019 has some worried that's changing.
Eleven biopharmas declared bankruptcy in 2019, more than any other year since at least 2011. Rising market pressures, coupled with legal liabilities, risk more companies falling to zero, experts warn.
By Andrew Dunn • Nov. 19, 2019 -
Deep DiveThe running list of 2019 biopharma bankruptcies
From antibiotic developers like Achaogen to opioid drugmakers like Purdue and Insys, 2019 saw an uptick in biopharmas filing for Chapter 11.
By Andrew Dunn • Nov. 19, 2019 -
Deep Dive31 biopharmas at high risk of bankruptcy in 2020
BioPharma Dive dug into data from a credit monitoring firm to identify drugmakers at high risk of going bankrupt, including companies like Teva, Bausch Health and Novavax.
By Andrew Dunn • Nov. 19, 2019 -
Novartis reshapes China R&D hub to reflect rapidly evolving market
The Swiss pharma giant is ending drug discovery efforts and shifting resources toward early development and commercial activities, a move that will eliminate around 150 jobs in the near term.
By Jacob Bell • UPDATED: Nov. 18, 2019 at 2:19 p.m. -
Novartis sickle cell drug wins FDA approval
Adakveo is only the second treatment approved in two decades for the painful blood clots caused by the rare disease.
By Jonathan Gardner • Nov. 15, 2019 -
Novartis' Sandoz builds global generics presence with Japan acquisition
Sandoz will pay approximately $331 million upfront for a Japan-focused subsidiary of Aspen Pharmacare.
By Andrew Dunn • Nov. 11, 2019 -
5 updates from Teva's busy quarter: A new CFO, a biosimilar launch and a migraine miss
Teva's stock went in an unfamiliar direction Thursday — up — as the pharma slightly beat Wall Street sales expectations with its quarterly results.
By Andrew Dunn • Nov. 07, 2019 -
AstraZeneca's China ambitions grow with new R&D investments
Already a leader in China, the British pharma is doubling down with plans to open two new centers and launch a $1 billion biotech investment fund.
By Jonathan Gardner • Nov. 06, 2019 -
Strong sales buoy pharma even as risks grow
Pfizer and Merck are the latest large drugmakers to post better-than-expected third quarter sales, a picture of strength that belies rising threats to the industry.
By Ned Pagliarulo • Oct. 29, 2019 -
Pfizer's heart drug impresses with fast US launch
Vyndaqel sales contributed to a 7% jump in the pharma's core drugs business, though overall third quarter sales fell compared to the same period a year ago.
By Andrew Dunn • Oct. 29, 2019 -
AstraZeneca joins Bristol-Myers' run at Merck in lung cancer
Imfinzi plus chemotherapy kept patients from progressing as quickly as chemo alone in a key study, but oncologists will need to see survival and safety data.
By Jonathan Gardner • Oct. 28, 2019 -
Allergan pays $750M to rid itself of Namenda antitrust charges
A class action suit followed the New York attorney general in claiming the big pharma tried to delay generic competition to its Alzheimer's drug.
By Jonathan Gardner • Oct. 28, 2019 -
GSK advances new antibiotic into Phase 3 studies
The drug is the first in a new antibiotic class, said the British pharma, which is one of just a few large drugmakers still developing antibacterial treatments.
By Andrew Dunn • Oct. 28, 2019 -
AstraZeneca blood cancer drug heading for showdown with AbbVie's
Competitive data from a Calquence leukemia study could help the U.K.-based big pharma add to its growing oncology sales.
By Jonathan Gardner • Oct. 24, 2019 -
J&J cuts profits to account for proposed opioid settlement
Under a deal in principle reached with several states, J&J would contribute $4 billion to resolve the many opioid lawsuits facing the pharma.
By Ned Pagliarulo • Oct. 24, 2019 -
Longtime Lilly diabetes chief Conterno to step down
Current head of Lilly's insulin division Mike Mason will take Conterno's place as the pharma confronts a challenging market for glucose-lowering drugs.
By Jonathan Gardner • Oct. 23, 2019 -
Teva offers $23B of Suboxone to get out of opioid litigation
Whether such a deal would be widely accepted wasn't clear, however, amid reports attorneys for plaintiff municipalities had already rejected Teva's "agreement in principle."
By Jonathan Gardner • Oct. 21, 2019 -
Drug distributors, Teva settle in Ohio opioid case
The companies, which include AmerisourceBergen, McKesson and Cardinal Health, will pay $260 million to two Ohio counties to avoid a trial.
By Jonathan Gardner • UPDATED: Oct. 21, 2019 at 4:53 p.m. -
GSK hands 2 of its less profitable vaccines to Bavarian Nordic
The deal, worth about $335 million upfront, will help GSK simplify its supply chain and allow it to reinvest in higher growth areas, according to the company.
By Jacob Bell • Oct. 21, 2019 -
Merck to lay off 500 US-based commercial employees
Affected employees will depart on Jan. 3, 2020, said the drugmaker, which claimed the cuts are not part of a new restructuring.
By Andrew Dunn • Oct. 18, 2019 -
Merck's Ebola vaccine wins key European vote
Erevebo has already been administered to 274,000 people, and data indicate it is effective against the virus currently causing an African outbreak.
By Jonathan Gardner • Oct. 18, 2019 -
Sanofi investing in gene therapy as R&D focus turns toward rare disease
R&D chief John Reed told BioPharma Dive Sanofi is retrofitting a vaccine facility in France to produce the viral vectors needed to deliver gene therapies.
By Andrew Dunn • Oct. 17, 2019 -
Lilly cancer drug pipeline hit by trial setback
Pegilodecakin, an immunotherapy acquired in the pharma's $1.6 billion deal for Armo BioSciences, failed to extend survival in patients with pancreatic cancer.
By Ned Pagliarulo • Oct. 16, 2019
